REFERENCES

1. 1. Amin‐Esmaeili M, Farokhnia M, Susukida R, Leggio L, Johnson RM, Crum RM, et al. Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: findings from 13 multisite randomized clinical trials. Addiction. 2024;119:833–843. https://doi.org/10.1111/add.16409
2. 1. Carroll KM, Kiluk BD, Nich C, DeVito EE, Decker S, LaPaglia D, et al. Toward empirical identification of a clinically meaningful indicator of treatment outcome: features of candidate indicators and evaluation of sensitivity to treatment effects and relationship to one year follow up cocaine use outcomes. Drug Alcohol Depend. 2014;137:3–19. https://doi.org/10.1016/j.drugalcdep.2014.01.012
3. 1. Cumming C, Troeung L, Young JT, Kelty E, Preen DB. Barriers to accessing methamphetamine treatment: a systematic review and meta‐analysis. Drug Alcohol Depend. 2016;168:263–273. https://doi.org/10.1016/j.drugalcdep.2016.10.001
4. 1. Wallach JD, Krystal JH, Ross JS, O'Malley SS. Characteristics of ongoing clinical trials for alcohol use disorder registered on ClinicalTrials.gov. JAMA Psychiatry. 2020;77(10):1081–1084. https://doi.org/10.1001/jamapsychiatry.2020.1167
5. 1. Shmulewitz D, Aharonovich E, Witkiewitz K, Anton RF, Kranzler HR, Scodes J, et al. The World Health Organization risk drinking levels measure of alcohol consumption: prevalence and health correlates in nationally representative surveys of U.S. adults, 2001‐2002 and 2012‐2013. Am J Psychiatry. 2021;178(6):548–559. https://doi.org/10.1176/appi.ajp.2020.20050610